Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Well what a fantastic set of results and a credit to the EKF team. In addition to comments below I'm also greatly interested in the further potential spin offs that will arise from EKF's MSIP partnership with Mount Sinai. The in-species dividends from EKF and spinoffs ( RENX, VRCI, Trellus ) have been extremely lucrative for all us shareholders. As an example the value of my RENX holding is now equivalent to approximately 50% of my EKF holding. Show me where else you can get this performance. Happy Days. Pontil
3 to 4 M Sale....... So 0.6 -0.8% of total stock in one trade. I believe this is likely to be an initial investor who bought in at relisting taking a 100% ish profit selling to a bigger player. I'm not aware of a lock in, or did I miss something? De-risking their initial outlay. Not a bad return. It'll be interesting if this leads to a holding RNS. Especially who this maybe. We'll see. I've always been of the opinion that every seller is matched by a buyer. So someone has confidence. Have fun. Pontil
Email received from IG.
1. We are increasing margins so that all positions on these shares will have a margin requirement of 100% at 3pm on Friday 26 February
2. Please close positions by Monday 29 March 2021, from which point we will start to close any remaining open positions
So we insist on 100% and we will close your long CFD position ( one held for > 3 years....NCT, MYN, AOGL.... ). £k's of profit to them and no chance to recover. Market manipulation?
IG issue a statement that materially affects a share's SP ( as here downwards ) and insists it will close your position by the end of march because it suits them. Is this legal? Is this within FCA's rules? Does this bring the market in to disrepute?
Very underhand.
Donmac, from their full year report 27/10 they stated:
Medicare national pricing for KidneyIntelX set at $950 per reportable test result, effective through December 2022.
I know some of our other posters are better at putting this into realizable profits. So for the US alone based on 100,000 tests it will yield revenues of $95M. 1M tests .... $950M...... = Profit of?????
Now how many tests will be taken each year in the US? What about other markets?
Buy out target is what we are becoming.
Pontil
Scooby, further to my earlier question on RENX IP. Does it extend beyond the Renal space. Can the same tools/alogorithms/ correlations etc be applied in other fields too. I'm wondering if there are many. If so the Mt Sinai connection will deliver this. Great to see the rise. Happy weekend. Pontil
EKF Diagnostics Holdings plc (AIM: EKF), the?AIM listed point-of-care business, announces that strong trading in October, combined with expected orders for the remainder of the year, will result in full year performance ahead of market expectations, which have already been revised upwards several times this year.
A significantly improved trading in the core business in the final quarter, along with continued orders for the PrimeStore MTM COVID-19 sample collection device underpins the Board's confidence of a strong full year performance.
EKF now expects to deliver Group revenues and adjusted EBITDA for the year ending 31 December 2020 comfortably ahead of market consensus, with expectations currently set at £60m for revenues and adjusted EBITDA of £23m.